STOK (Stoke Therapeutics) Other Long Term Assets : $0.72 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Other Long Term Assets?

Stoke Therapeutics's other long-term assets for the quarter that ended in Dec. 2024 was $0.72 Mil.

Stoke Therapeutics's quarterly other long-term assets increased from Jun. 2024 ($0.49 Mil) to Sep. 2024 ($0.49 Mil) and increased from Sep. 2024 ($0.49 Mil) to Dec. 2024 ($0.72 Mil).

Stoke Therapeutics's annual other long-term assets increased from Dec. 2022 ($0.57 Mil) to Dec. 2023 ($0.57 Mil) and increased from Dec. 2023 ($0.57 Mil) to Dec. 2024 ($0.72 Mil).

Stoke Therapeutics Other Long Term Assets Historical Data

The historical data trend for Stoke Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Other Long Term Assets Chart

Stoke Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long Term Assets

Get a 7-Day Free Trial

0.21

0.57

0.72

Stoke Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Long Term Assets	Get a 7-Day Free Trial															0.57	0.57	0.49	0.49	0.72

Stoke Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Stoke Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (NAS:STOK) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

0GT:Germany

Address

45 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.stoketherapeutics.com

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Executives

Jonathan Allan	officer: General Counsel & Corp Sec	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Kaye Edward M. Md	director, officer: CEO	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Barry Ticho	officer: Chief Medical Officer	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Skorpios Trust	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Huw M. Nash	officer: COO & CBO	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Stephen J Tulipano	officer: CFO	C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Atp Life Science Ventures, L.p.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Atp Iii Gp, Ltd.	10 percent owner	230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169
Montrago Trustees Ltd	10 percent owner	195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030
Blue Horizon Enterprise Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Ezbon International Ltd	10 percent owner	3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110
Gene Liau	officer: EVP Research & Preclinical Dev	C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730
Arthur A Levin	director	1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Arthur Tzianabos	director	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730